Upadacitinib for active large-vessel giant cell arteritis
Part of Brain & nervous system, Heart & circulation, Immune system & allergy, Skin clinical trials.
This trial tests a medicine called upadacitinib (an anti-JAK pill) for people with giant cell arteritis that affects the large arteries, especially the aorta. It is for those whose disease is active despite trying another treatment called tocilizumab, and aims to reduce inflammation and prevent damage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and have a confirmed diagnosis of giant cell arteritis (blood vessel inflammation)
- You have active inflammation in the aorta (the main artery from your heart) seen on a scan
- You have already tried a medicine called tocilizumab and it didn't work or you couldn't take it
- You do not have certain infections (like HIV, hepatitis B or C) or a history of cancer in the past 5 years
- You have not had a blood clot or severe heart problems in the past
- You are not pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests the drug tocilizumab (Actemra) to see if it helps reduce swelling in the aorta in people with giant cell arteritis (GCA) who are newly diagnosed or have had a flare. It may offer a targeted treatment for aortitis without using high-dose steroids.
This trial tests whether a drug called bosentan, which is usually used for other conditions, can help calm the inflammation in giant cell arteritis and reduce symptoms. You would take it in addition to your usual treatment, and it might help lower the dose of steroids you need.
This study looks at immune cells called B-cells in people with giant cell arteritis (a condition causing inflammation in blood vessels) and other immune disorders, to see if targeting these cells could be a new treatment. It involves imaging and blood tests.
This study compares stopping tocilizumab (Actemra) completely versus reducing the dose in people whose giant cell arteritis has been well controlled for at least a year. The goal is to find out which approach keeps the disease in remission while reducing medication side effects.
This trial tests two drugs, dapagliflozin and bosentan, to see if they help people with large vessel vasculitis who have been in remission for at least 6 months. The goal is to prevent flares and improve blood vessel health.
This trial tests a fast-track process to quickly diagnose giant cell arteritis (GCA), a condition that causes blood vessel inflammation. It may help patients get the right care faster.
Hear when a new Giant Cell Arteritis (GCA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.